Statin use and outcomes of oncologica... - Fight Prostate Ca...

Fight Prostate Cancer

2,956 members1,313 posts

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer - From the Finnish poulation, Nature, 11/01/23

CaptnMojoe profile image
2 Replies

As a follow-up to recent posts on statins and PCa, here is another Euopean study, this time from the Finns. As noted in the Abstract below, they come to the conclusion of no/little benefit for crPCa, but maybe some for csPCa.

The apparent pooling of data for specific type/form of statin does not provide any guidance on any benefit of one vs another.

* * *

Abstract

To compare the effect of statin use in relation to castration-resistant prostate cancer (CRPC) treatment, we assessed the risk of ADT-treated PCa-patients to initiate CRPC treatment by statin use and the outcomes of CRPC treatment by statin use. Our study cohort consisted of 1169 men who participated in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) and initiated androgen deprivation therapy (ADT) during the follow-up (1996-2017). Statin use was associated with slightly decreased risk of initiating CRPC treatment (HR 0.68; 95% CI 0.47-0.97) with a 5.7 years' median follow-up until CRPC for non-users and 7.5 years for statin users. The risk of discontinuation of first or second line CRPC treatment due to inefficacy was not modified by statin use and the results remained similar in subgroup analysis assessing separately patients treated with taxans or androgen receptor signaling inhibitors. We observed an inverse association between statin use and the risk of initiation of the CRPC treatment. No beneficial risk modification by statin use during CRPC treatment was observed. These results suggest that statins might be beneficial during hormone-sensitive phase but not in the later phases of prostate cancer treatment.

* * *

Full paper here:

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer, Nature, Scientific Reports, 2023, Nov 01.

nature.com/articles/s41598-...

Saluti - Mojoe

Written by
CaptnMojoe profile image
CaptnMojoe
To view profiles and participate in discussions please or .
Read more about...
2 Replies
PCaWarrior profile image
PCaWarrior

Meta analysis of 3 trials.

Not a cure. Inexpensive, conventional, reduces CVD risk, simple, very low sides (most of them are present only in people who expect side effects from statins).

statin
PhilipSZacarias profile image
PhilipSZacarias

Thank you for posting

Not what you're looking for?

You may also like...

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy

New paper from Spain [1]. "... we will review those strategies and drugs that are able to...
pca2004 profile image

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance, Int J Mol Sci. 2022 Nov; 23(21): 13521

This is by far the best overview paper I have seen on the topic of AR metabolism and the nature of...
cujoe profile image

Statin use and mortality risk in men on ADT.

New ADT study from Hong Kong (1). "A total of 4920 patients were included, consisting of 2578...
pca2004 profile image

The Role of HSD3B1 in Prostate Cancer Progression and Treatment

I don't think I was tested against this gene, so I think it could be important for me as well. A...
Maxone73 profile image

Supraphysiological Androgens [SPA] Promote Tumor Suppressive Activity of the AR Through cMYC Repression and Recruitment of the DREAM Complex

New study [1].  I have struggled to understand how Denmeade’s BAT (Bipolar Androgen Therapy)...
pca2004 profile image